candoxatrilat

USAN lists candoxatrilat (UK-73,967) with RN 123122-54-3

Also Known As:

4-((2-carboxy-3-(2-methoxyethoxy)propyl)-1-cyclopentanecarbonylamino)-1-cyclohexanecarboxylic acid; U 73967; UK 69578; UK 73967; UK-69,578; UK-69578; UK-73,967; UK-73967; candoxatrilat, 4(S)-cis isomer; Cyclohexanecarboxylic acid, 4-(((1-(2-carboxy-3-(2-methoxyethoxy)propyl)cyclopentyl)carbonyl)amino)-, cis-(+-)-

Networked: 12 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclohexanes: 3
        Cyclohexanecarboxylic Acids
        candoxatrilat: 12
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Cyclohexanecarboxylic Acids
      - candoxatrilat: 12

Experts

1.	McAllen, Robin M: 1 article (10/2008)
2.	Salo, Lauren M: 1 article (10/2008)
3.	Thomas, Colleen J: 1 article (10/2008)
4.	Woods, Robyn L: 1 article (10/2008)
5.	Barker, Laura: 1 article (01/2007)
6.	Beaumont, Kevin: 1 article (01/2007)
7.	Burring, Denise J: 1 article (01/2007)
8.	Coggon, Sara: 1 article (01/2007)
9.	Cook, Andrew S: 1 article (01/2007)
10.	Corless, Martin: 1 article (01/2007)

Related Diseases

1.	Heart Failure 05/01/1995 - "In a double-blind crossover trial, the effects of intravenous boluses of saline vehicle (placebo) and 50, 100 and 200 mg of candoxatrilat were compared on separate days in 12 patients with heart failure. " 05/01/1995 - "Candoxatrilat given acutely causes diuresis, even in patients with moderately severe heart failure." 05/01/1995 - "Our primary objective was to compare the effects of three different doses of candoxatrilat with the effects of placebo on urinary volume in patients with moderately severe heart failure. " 05/01/1995 - "Renal response to candoxatrilat in patients with heart failure." 10/01/1992 - "This was a single blind, randomised comparison of +/- candoxatrilat and placebo in patients with mild heart failure. "
2.	Fistula 11/01/1996 - "1. The present studies compare the early renal response to (a) an endopeptidase-24.11 (E-24.11) inhibitor (candoxatrilat) (b) an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) and (c) the combination of endopeptidase-24.11 and ACE inhibition in the rat A-V fistula model of chronic volume overload. " 09/01/1992 - "Both candoxatrilat and SC 46542 increased sodium and cyclic GMP excretion in the rat A-V fistula model of heart failure, a model hyporesponsive to infusions of ANP, without significant change in blood pressure.7. These data show that candoxatrilat and SC 46542 do not simply reproduce the effects of an ANP infusion but preferentially enhance the natriuretic response to ANP. "
3.	Fibrosis (Cirrhosis) 11/01/2005 - "We determined the effects of NEP inhibition by candoxatrilat on hormonal status, liver function and arterial and portal pressures in rats with CCl4-induced cirrhosis. " 06/01/2006 - "The purpose of this study was the assessment of kidney neutral endopeptidase expression and responses to candoxatrilat (a specific inhibitor of this enzyme) in rats with CCl4-induced cirrhosis. "
4.	Hypoxia (Hypoxemia) 12/01/1991 - "3.4.24.11), UK 73,967 (candoxatrilat), was undertaken in rats, in which chronic hypoxia was used as a stimulus to induce pulmonary hypertension and right ventricular hypertrophy. " 11/01/1992 - "We have studied the acute effect of brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) on pulmonary vascular tone in normoxia and acute hypoxia in the absence and presence of a specific inhibitor of neutral endopeptidase 24.11 (NEI, UK 73, 967, candoxatrilat; Pfizer) in the isolated and blood-perfused rat lung preparation. "
5.	Psychological Sexual Dysfunctions (Sexual Arousal Disorder) 01/01/2007 - "A series of substituted glutaramides were synthesised using Candoxatrilat 1 as a lead and evaluated for potency against neutral endopeptidase (NEP) as a potential treatment for female sexual arousal disorder (FSAD). "

Related Drugs and Biologics

1.	Neprilysin (Neutral Endopeptidase)
2.	Atrial Natriuretic Factor (ANF)
3.	Lisinopril (Prinivil)
4.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
5.	Enzymes
6.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
7.	Brain Natriuretic Peptide (Natrecor)
8.	Sodium
9.	Protease Inhibitors (Protease Inhibitor)
10.	Prodrugs

Related Therapies and Procedures

1.	Therapeutics